X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CTI-1601 (nomlabofusp) is a recombinant fusion protein intended to deliver human frataxin to the mitochondria of patients. It is being developed for the treatment of Friedreich’s Ataxia.
Lead Product(s): Nomlabofusp
Therapeutic Area: Genetic Disease Product Name: CTI-1601
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2024
Details:
Larimar intends to use the net proceeds from the proposed offering to support the development of CTI-1601 (nomlabofusp), a recombinant fusion protein, for the treatment for Friedreich’s ataxia.
Lead Product(s): Nomlabofusp
Therapeutic Area: Genetic Disease Product Name: CTI-1601
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Leerink Partners
Deal Size: $172.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 16, 2024
Details:
Larimar intends to use the net proceeds from the proposed offering to support the development of CTI-1601 (nomlabofusp), a recombinant fusion protein, for the treatment for Friedreich’s ataxia.
Lead Product(s): Nomlabofusp
Therapeutic Area: Genetic Disease Product Name: CTI-1601
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Leerink Partners
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 14, 2024
Details:
Larimar intends to use the net proceeds to support the development of CTI-1601 (nomlabofusp), a recombinant fusion protein intended to deliver human frataxin to patients with Friedreich's ataxia, and other pipeline candidates.
Lead Product(s): Nomlabofusp
Therapeutic Area: Genetic Disease Product Name: CTI-1601
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Leerink Partners
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering February 13, 2024
Details:
CTI-1601 (nomlabofusp) is a recombinant fusion protein intended to deliver human frataxin to the mitochondria of patients. It is being developed for the treatment of Friedreich’s Ataxia.
Lead Product(s): Nomlabofusp
Therapeutic Area: Genetic Disease Product Name: CTI-1601
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2024
Details:
CTI-1601 (nomlabofusp) is a recombinant fusion protein intended to deliver human frataxin to the mitochondria of patients with Friedreich’s ataxia who are unable to produce enough of this essential protein.
Lead Product(s): Nomlabofusp
Therapeutic Area: Genetic Disease Product Name: CTI-1601
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 25, 2023
Details:
CTI-1601 is a recombinant fusion protein intended to deliver human frataxin to the mitochondria of patients with Friedreich’s ataxia who are unable to produce enough of this essential protein.
Lead Product(s): CTI-1601
Therapeutic Area: Genetic Disease Product Name: CTI-1601
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2023
Details:
Larimar intends to use the net proceeds from the offering to support the clinical development of CTI-1601, and for working capital and general corporate purposes, including research and development expenses.
Lead Product(s): CTI-1601
Therapeutic Area: Genetic Disease Product Name: CTI-1601
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Guggenheim Securities
Deal Size: $80.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 16, 2022
Details:
Larimar intends to use the net proceeds from the offering to support the clinical development of CTI-1601, and for working capital and general corporate purposes, including research and development expenses.
Lead Product(s): CTI-1601
Therapeutic Area: Genetic Disease Product Name: CTI-1601
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Guggenheim Securities
Deal Size: $70.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 14, 2022
Details:
CTI-1601 is a recombinant fusion protein intended to deliver human frataxin to the mitochondria of patients with Friedreich’s ataxia who are unable to produce enough of this essential protein.
Lead Product(s): CTI-1601
Therapeutic Area: Genetic Disease Product Name: CTI-1601
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
